Today’s draft guidance is the first time NICE has made recommendations about the use of an HIV treatment since these came under NICE’s remit in 2019.
It is estimated that around 13,000 people will now be eligible for treatment with cabotegravir with rilpivirine in England.
Current treatment for HIV‑1 is lifelong antiretroviral tablets taken each day. The aim is to keep the number of virus particles in the blood (the viral load) so low that it cannot be detected or transmitted between people.
Cabotegravir (also called Vocabria and made by Viiv Healthcare) with rilpivirine (also called Rekambys and made by Janssen), is recommended as an option for adults with HIV-1 infection when antiretroviral medicines they are already taking to treat HIV-1 have kept the virus at a low level and where there is no evidence to suspect viral resistance, and no previous failure of other anti-HIV-1 medicines called nonnucleoside reverse transcriptase inhibitors (NNRTIs) and integrase inhibitors (INIs).
Clinical trial results show that cabotegravir with rilpivirine is as effective as oral antiretrovirals at keeping the viral load low.
Both cabotegravir and rilpivirine are administered as 2 separate injections every 2 months, after an initial oral (tablet) lead-in period.
Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Assessment at NICE, said: “Despite scientific advances HIV is still incurable, but the virus can be controlled by modern treatment. However, for some people, having to take daily multi-tablet regimens can be difficult because of drug-related side effects, toxicity, and other psychosocial issues such as stigma or changes in lifestyle. The committee heard that stigma remains an issue for people living with HIV and can have a negative impact on people’s health and relationships.
“We’re pleased therefore to be able to recommend cabotegravir with rilpivirine as a valuable treatment option for people who already have good levels of adherence to daily tablets, but who might prefer an injectable regimen with less frequent dosing.”
The FAD has been sent to consultees for this appraisal who have the opportunity to appeal against it. If no appeals are received NICE expects to publish final guidance on cabotegravir with rilpivirine for treating HIV-1 infection in January 2022. Commissioners will then need to comply with the recommendations in the guidance within 3 months of its date of publication.
